Recombinant Human IL27A Protein，His

Interleukin-27 (IL-27) is a cytokine belonging to the interleukin-6 (IL-6) and IL-12 family, which plays a pivotal role in regulating immune responses. It is primarily produced by dendritic cells and macrophages and acts on various immune cells, including T cells, to promote Th1 differentiation and inhibit Th2 responses. The recombinant protein of IL-27, known as IL27A, has garnered significant interest in immunology and therapeutic research due to its potential applications in treating autoimmune diseases, infections, and cancers. IL27A exhibits both pro-inflammatory and anti-inflammatory properties, which complicate its role in disease but highlights its therapeutic promise. Studies have shown that IL27A can enhance the activity of cytotoxic T lymphocytes, thereby boosting anti-tumor immunity, while also modulating regulatory T cells to reduce excessive inflammatory responses. Furthermore, research into IL27A is exploring its mechanisms of action, signaling pathways, and interactions with other cytokines, which could lead to novel therapeutic strategies that leverage its dual roles in the immune system. Additionally, understanding the structural and functional characteristics of recombinant IL27A can facilitate the development of more effective cytokine-based therapies, underscoring the importance of continued research in this area. As the understanding of IL27A advances, it holds the potential to inform new treatment modalities for various immune-related conditions, making it a critical focus for both basic and translational research in immunology.